Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) [Phase 2]

View source ↗

Summary

The VALIANT Phase 2 trial evaluating Verekitug (UPB-101) for severe asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Verekitug (UPB-101)

Snippet

Sponsor: Upstream Bio Inc. | Conditions: Severe Asthma | Phase 2 | Status: COMPLETED